ArticleBJUI compass2025
The past, present and future of penile cancer in the Nordic countries. Results from NORDCAN.
Article in BJUI compass, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multiparametric Magnetic Resonance Imaging Without Artificial Erection for Preoperative Staging of Primary Penile Carcinoma.European urology open science · 2026Article
- Histological and Molecular Evaluation of HPV in Primary Tumors and Lymph Node Metastases of Penile Cancer.Cancers · 2026Article
- Soluble immune checkpoint proteins as predictive biomarkers for lymph node metastases in penile cancer.Frontiers in immunology · 2026Article
- The past, present and future of penile cancer in the Nordic countries. Results from NORDCAN.BJUI compass · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This work aims to present epidemiological data on penile cancer from the Nordic region (Denmark, Finland, Iceland, Norway, Sweden) and discuss the results in light of the present knowledge and possible future treatment strategies. Patients and Methods: All patients diagnosed with penile cancer in the Nordic countries between 2000 and 2022 were identified in the NORDCAN database. Data on the number of new cases per year, incidence (presented as an age-standardized rate using the Nordic population as a reference), prevalence, mortality, relative survival and predictions on the future societal impact of this cancer was retrieved. Results: A total of 6106 cases of penile cancer were registered in a population that increased from about 12-14 million men over the period. The age-standardized incidence has significantly increased over time and is now above 2.0 per 100 000 men. Currently, more than 300 new cases are diagnosed each year, and more than 3000 men live with a penile cancer diagnosis. Mortality, as well as both 1-year and 5-year relative survival have, however, remained nearly unchanged. Using the NORPRED model, it is predicted that the yearly number of penile cancer cases will continue to increase in all the countries investigated over the next decade. Conclusion: Penile cancer incidence and prevalence have increased in the Nordic region over the last 20 years. Mortality and survival, however, have remained unchanged. The number of new penile cancer cases is predicted to increase over the next decade. Better treatment options for these patients are therefore urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.